A Post Marketing Surveillance study to assess the efficacy and safety of PIVASTA (Pitavastatin) Tablets in patients of Type 2 Diabetes mellitus and dyslipidemia

Cadila Healthcare0 个研究点目标入组 500 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients of either sex, 18-75 years of age..
•2. Patients who are diagnosed of Type 2 Diabetes
•3. Patients with any one of the following: serum Low density Lipoprotein (LDL) cholesterol > 100 mg/dl, Or serum high density lipoprotein (HDL) cholesterol < 40 mg/dl (for male), HDL < 50 mg/dl (for female), Or serum triglycerides (TG) > 150 mg/dl

•Patients who is:
•1. Known to have hypersensitivity to pitavastatin
•2. Having active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels
•3. Pregnant woman or may become pregnant in next 3 months
•4. Nursing mother
•5. on cyclosporine
•6. Has change/titration in anti-diabetic medications in last one month
•7. On statin or other lipid lowering therapy during last 3 months
•8. creatinine clearance < 30 ml/min/1.73 m2
•9. not willing to give written consent for enrollment in the study.

发起方

Cadila Healthcare